Related Experiment Video
Updated: Jul 4, 2026
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth
Ailyn Choo1, Patricia Palladinetti, Tiffany Holmes
1Children's Cancer Institute Australia for Medical Research, Randwick, Australia.
Abstract:
Interferon regulatory factor (IRF) 1 and its functional antagonist IRF2 were originally discovered as transcription factors that regulate the interferon-beta gene. Control of cell growth has led to the definition of IRF1 as a tumour suppressor gene and IRF2 as an oncogene. Clinically, approximately 70% of cases of acute myeloid leukaemia demonstrate dysregulated expression of IRF1 and/or IRF2. Our previous studies have shown that human leukaemic TF-1 cells exhibit abnormally high expression of both IRF1 and IRF2, the latter acting to abrogate IRF1 tumour suppression, making these cells ideal for analysis of down-regulation of IRF2 expression. A novel G418 screening protocol was developed and used for identifying effective siRNA that targets IRF2 (siIRF2). Using optimized siIRF2 in leukaemic TF-1 cells, IRF2 was down-regulated by approximately 70% at both mRNA and protein levels. Phenotypically, this resulted in growth inhibition associated with G2/M arrest as well as induction of polyploidy, differentiation and apoptosis. In contrast to these results, siIRF2 targeting did not affect normal haematopoietic stem/progenitor cell growth. These results indicate the potential utility of IRF2 inhibition as a therapeutic approach to cancer.
Insights
Targeting Interferon Regulatory Factor 2 (IRF2) in acute myeloid leukaemia cells with siRNA inhibited cancer growth and induced cell death, without harming normal stem cells. This suggests IRF2 inhibition is a promising cancer therapy.
Area of Science:
- Molecular Biology
- Cancer Research
- Gene Regulation
Background:
- Interferon regulatory factor (IRF) 1 and IRF2 are key transcription factors regulating the interferon-beta gene.
- IRF1 functions as a tumor suppressor, while IRF2 acts as an oncogene, with dysregulated expression observed in ~70% of acute myeloid leukaemia (AML) cases.
- Leukaemic TF-1 cells show high IRF1 and IRF2 expression, with IRF2 abrogating IRF1's tumor suppressive function, making them a model for IRF2 down-regulation studies.
Purpose of the Study:
- To investigate the effects of down-regulating IRF2 expression in leukaemic TF-1 cells.
- To assess the potential of IRF2 inhibition as a therapeutic strategy for cancer.
Main Methods:
- Development of a G418 screening protocol to identify effective small interfering RNA (siRNA) targeting IRF2 (siIRF2).
- Application of optimized siIRF2 to leukaemic TF-1 cells to achieve significant down-regulation of IRF2 at mRNA and protein levels.
- Evaluation of phenotypic changes in leukaemic cells, including growth inhibition, cell cycle arrest, polyploidy, differentiation, and apoptosis.
- Assessment of siIRF2 effects on normal haematopoietic stem/progenitor cell growth.
Main Results:
- Optimized siIRF2 successfully down-regulated IRF2 expression by approximately 70% in leukaemic TF-1 cells.
- IRF2 down-regulation led to significant phenotypic changes: growth inhibition, G2/M cell cycle arrest, polyploidy induction, differentiation, and apoptosis.
- Crucially, siIRF2 targeting did not adversely affect the growth of normal haematopoietic stem/progenitor cells.
Conclusions:
- IRF2 down-regulation via siRNA effectively inhibits leukaemic cell growth and induces anti-cancer effects.
- IRF2 inhibition demonstrates therapeutic potential as a targeted cancer treatment, particularly for AML.
- The selective effect on leukaemic cells versus normal stem cells highlights the safety profile of this approach.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi
01:30Inhibitors of Viral Protein Synthesis
02:23Abnormal Proliferation
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...